Clinical Trial Update: A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 study comparing PROCRIT (epoetin alfa) 80,000 units every four weeks with 40,000 units every two weeks in cancer patients not receiving chemotherapy was…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Anemia, Cancer | Phase 2 | Status: TERMINATED